Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Adjusted hazard ratios for 5-year OS in patients with IBC presenting with stage IV disease

From: Metastatic behavior and overall survival according to breast cancer subtypes in stage IV inflammatory breast cancer

  Hazard ratio (95% CI) p value
Age 1.01 1.00–1.01 0.168
Year of diagnosis 0.98 0.95–1.02 0.352
Clinical nodal stage
 N0 1 (ref)   
 N1 1.15 0.78–1.68 0.468
 N2 1.23 0.74–2.07 0.414
 N3 1.32 0.88–1.99 0.174
Surgery
 No 1 (ref)   
 Yes 0.56 0.42–0.74 < 0.001
Chemotherapy
 Yes 1 (ref)   
 No 1.62 1.24–2.14 < 0.001
Targeted therapy
 Yes 1 (ref)   
 No 2.76 1.70–3.05 < 0.001
Antihormonal therapy
 Yes 1 (ref)   
 No 2.16 1.62–2.89 < 0.001
Radiation therapy
 Yes 1 (ref)   
 No 1.11 0.84–1.46 0.457
Molecular subtype
 HR+/HER2− 1 (Ref)   
 HR+/HER2+ 1.17 0.86–1.61 0.319
 HR−/HER2+ 1.59 1.12–2.24 0.009
 HR−/HER2− 1.94 1.41–2.67 < 0.001
Location of metastases
 Bone only 1 (ref)   
 Liver only 0.86 0.56–1.33 0.507
 Lung only 1.27 0.81–1.99 0.292
 Other 0.99 0.69–1.40 0.934
 Multiple organs 1.32 1.04–1.68 0.021
  1. Abbreviations: ref. refererence, OR odds ratio, CI confidence interval, HR hormone receptor, HER2 human epidermal growth factor receptor-2. p values indicated in italics are considered as statistically significant (p < 0.05)